DRTS icon

Alpha Tau Medical

3.81 USD
-0.02
0.52%
At close Updated Sep 12, 4:00 PM EDT
1 day
-0.52%
5 days
4.96%
1 month
17.23%
3 months
24.1%
6 months
43.23%
Year to date
22.9%
1 year
58.75%
5 years
-68.01%
10 years
-68.01%
 

About: Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.

Employees: 125

0
Funds holding %
of 7,462 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

68% more capital invested

Capital invested by funds: $2.94M [Q1] → $4.95M (+$2.01M) [Q2]

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

0.2% more ownership

Funds ownership: 1.67% [Q1] → 1.87% (+0.2%) [Q2]

0% more funds holding

Funds holding: 23 [Q1] → 23 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$9
136% upside
Avg. target
$9
136% upside
High target
$9
136% upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Yi Chen
$9
Buy
Reiterated
3 Sep 2025

Financial journalist opinion

Neutral
GlobeNewsWire
11 days ago
Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
– First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program –
Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
Neutral
GlobeNewsWire
17 days ago
Alpha Tau to Participate in Five September Investor Conferences
JERUSALEM, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present and meet investors in the following five investor conferences in September 2025.
Alpha Tau to Participate in Five September Investor Conferences
Neutral
GlobeNewsWire
1 month ago
Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update
- FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer -
Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Neutral
GlobeNewsWire
3 months ago
Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update
- Interim Jan-2025 results from three trials of Alpha DaRT ® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate , impressive overall survival in sub-group analys e s, and positive safety profile -
Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update
Neutral
GlobeNewsWire
4 months ago
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors
JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq:  DRTS , DRTSW ) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, and Chairman of the Board of Oramed Pharmaceuticals Inc., (“Oramed”), has been appointed to the Company's Board of Directors (“Board”). The appointment follows the recent closing of a strategic investment between the Company and an affiliate of Oramed.
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors
Neutral
GlobeNewsWire
4 months ago
Alpha Tau to Participate in May Investor Conferences
JERUSALEM, May 06, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will presentation in the following investor conferences in May 2025.
Alpha Tau to Participate in May Investor Conferences
Neutral
PRNewsWire
4 months ago
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials across four indications, manufacturing scale-up, and commercialization efforts Partnership unites two innovative therapeutic delivery pioneers – Oramed's oral drug delivery platform with Alpha Tau's precision radiation delivery technology NEW YORK , April 28, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company"), (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, announced today that it has successfully closed a strategic investment in Alpha Tau Medical Ltd. (Nasdaq: DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®.
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Neutral
GlobeNewsWire
4 months ago
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that it has successfully closed a registered direct offering (the “offering”) whereby an affiliate of Oramed Pharmaceuticals Inc. (“Oramed”) (Nasdaq: ORMP) (TASE: ORMP) purchased 14,110,121 of Alpha Tau's ordinary shares, no par value, at a purchase price of $2.612 per ordinary share.
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
Neutral
GlobeNewsWire
5 months ago
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for the treatment of patients with recurrent glioblastoma (GBM) using the Alpha DaRT technology.
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
Neutral
GlobeNewsWire
6 months ago
Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update
- Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile -
Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update
Charts implemented using Lightweight Charts™